Theravance Biopharma, Inc.TBPHEarnings & Financial Report
Theravance Biopharma, Inc. is a global biopharmaceutical enterprise focused on researching, developing and commercializing innovative medicines for patients with serious, unmet medical needs, primarily targeting respiratory and infectious disease segments. It operates core markets across North America and Europe, partnering with global healthcare stakeholders to advance its therapy pipeline and deliver effective, accessible treatment options to underserved patient groups.
TBPH Q4 FY2025 Key Financial Metrics
Revenue
$45.9M
Gross Profit
N/A
Operating Profit
$20.0M
Net Profit
$61.0M
Gross Margin
N/A
Operating Margin
43.6%
Net Margin
133.0%
YoY Growth
144.7%
EPS
$1.18
Theravance Biopharma, Inc. Q4 FY2025 Financial Summary
Theravance Biopharma, Inc. reported revenue of $45.9M (up 144.7% YoY) for Q4 FY2025, with a net profit of $61.0M (up 493.0% YoY) (133.0% margin).
Key Financial Metrics
| Total Revenue | $45.9M |
|---|---|
| Net Profit | $61.0M |
| Gross Margin | N/A |
| Operating Margin | 43.6% |
| Report Period | Q4 FY2025 |
Theravance Biopharma, Inc. Annual Revenue by Year
Theravance Biopharma, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $107.5M).
Theravance Biopharma, Inc. Quarterly Revenue & Net Profit History
Theravance Biopharma, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $45.9M | +144.7% | $61.0M | 133.0% |
| Q3 FY2025 | $20.0M | +18.5% | $3.6M | 18.1% |
| Q2 FY2025 | $26.2M | +83.7% | $54.8M | 209.3% |
| Q1 FY2025 | $15.4M | +6.1% | $-13.6M | -88.2% |
| Q4 FY2024 | $18.8M | +6.8% | $-15.5M | -82.8% |
| Q3 FY2024 | $16.9M | +7.5% | $-12.7M | -75.3% |
| Q2 FY2024 | $14.3M | +3.7% | $-16.5M | -115.9% |
| Q1 FY2024 | $14.5M | +39.2% | $-11.7M | -80.4% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $14.5M | $14.3M | $16.9M | $18.8M | $15.4M | $26.2M | $20.0M | $45.9M |
| YoY Growth | 39.2% | 3.7% | 7.5% | 6.8% | 6.1% | 83.7% | 18.5% | 144.7% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $371.3M | $362.0M | $356.1M | $354.2M | $343.6M | $426.0M | $415.5M | $485.6M |
| Liabilities | $166.4M | $168.3M | $170.5M | $178.6M | $177.6M | $201.2M | $182.8M | $188.8M |
| Equity | $204.9M | $193.7M | $185.7M | $175.5M | $166.0M | $224.8M | $232.7M | $296.7M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-1.0M | $-4.4M | $-5.2M | $-902000 | $43.0M | $208.1M | $-6.5M | $-6.1M |